Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

View:
Post by beechguy on May 06, 2013 3:32pm

Q3 revenue

Anyone want to guess what Q3 revenue will come in at? Q3 2012 came in at 8.7mm. I am going say this is our first 10mm quarter ever (without milestones)

 

My guess is 10.2mm for a 16% QOQ increase. The market will probably yawn at another double digit growth quarter. I'm afraid while our current regime is in place, nobody really cares what happens.

 

beech

Comment by Nohandledzep on May 06, 2013 4:01pm
I have no idea Beech, but if there is a 16% Q over Q increase in revenue and a 3.2 mil loss, which one steals the headline in the quartely NR?    
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities